Patients were centrally randomised by fax ( 1:1 ) to FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab ( using permuted blocks of randomly varying size ) , stratified according to ECOG performance status , number of metastatic sites , white blood cell count , and alkaline phosphatase concentration .